Literature DB >> 27865193

Different clinical outcomes in patients with asymptomatic severe aortic stenosis according to the stage classification: Does the aortic valve area matter?

Takeshi Kitai1, Tomohiko Taniguchi2, Takeshi Morimoto3, Toshiaki Toyota2, Chisato Izumi4, Shuichiro Kaji1, Kitae Kim1, Naritatsu Saito2, Kazuya Nagao5, Tsukasa Inada5, Eri Minamino-Muta2, Takao Kato2, Moriaki Inoko6, Katsuhisa Ishii7, Tadaaki Koyama8, Ryuzo Sakata8, Yutaka Furukawa1, Takeshi Kimura9.   

Abstract

BACKGROUND: The ACC/AHA guidelines introduced a new classification of severe aortic stenosis (AS) mainly based on maximum jet velocity (Vmax) and mean pressure gradient (mPG), but not on aortic valve area (AVA). However, prognostic value of this new classification has not yet been fully evaluated. METHODS AND
RESULTS: We studied 1512 patients with asymptomatic severe AS enrolled in the CURRENT AS registry in whom surgery was not initially planned. Patients were divided into 2 groups: Group 1 (N=122) comprised patients who met the recommendation for surgery; high-gradient (HG)-AS (Vmax≥4.0m/s or mPG≥40mmHg) with ejection fraction (EF)<50%, or very HG-AS (Vmax≥5.0m/s or mPG≥60mmHg), and Group 2 (N=1390) comprised patients who did not meet this recommendation. Group 2 was further subdivided into HG-AS with preserved EF (HGpEF-AS, N=498) and low-gradient (LG)-AS, but AVA<1.0cm2 (N=892). The excess risk of Group 1 relative to Group 2 for the primary outcome measure (a composite of aortic valve-related death or heart failure hospitalization) was significant (adjusted HR: 1.92, 95%CI: 1.37-2.68, P<0.001). The excess risk of HGpEF-AS relative to LG-AS for the primary outcome measure was also significant (adjusted HR: 1.45, 95%CI: 1.11-1.89, P=0.006). Among LG-AS patients, patients with reduced EF (<50%) (LGrEF-AS, N=103) had extremely high cumulative 5-year incidence of all-cause death (85.5%).
CONCLUSION: Trans-aortic valve gradient in combination with EF was a good prognostic marker in patients with asymptomatic AS. However, patients with LGrEF-AS had extremely poor prognosis when managed conservatively.
Copyright © 2016 Elsevier Ireland Ltd. All rights reserved.

Entities:  

Keywords:  Follow-up studies; Prognosis; Surgery; Valves

Mesh:

Year:  2016        PMID: 27865193     DOI: 10.1016/j.ijcard.2016.11.092

Source DB:  PubMed          Journal:  Int J Cardiol        ISSN: 0167-5273            Impact factor:   4.164


  3 in total

Review 1.  The contemporary role of echocardiography in the assessment and management of aortic stenosis.

Authors:  Takeshi Kitai; Rayji S Tsutsui
Journal:  J Med Ultrason (2001)       Date:  2019-12-02       Impact factor: 1.314

2.  Asymptomatic versus Symptomatic Patients with Severe Aortic Stenosis.

Authors:  Norio Kanamori; Tomohiko Taniguchi; Takeshi Morimoto; Hiroki Shiomi; Kenji Ando; Koichiro Murata; Takeshi Kitai; Yuichi Kawase; Chisato Izumi; Makoto Miyake; Hirokazu Mitsuoka; Masashi Kato; Yutaka Hirano; Shintaro Matsuda; Kazuya Nagao; Tsukasa Inada; Hiroshi Mabuchi; Yasuyo Takeuchi; Keiichiro Yamane; Mamoru Toyofuku; Mitsuru Ishii; Eri Minamino-Muta; Takao Kato; Moriaki Inoko; Tomoyuki Ikeda; Akihiro Komasa; Katsuhisa Ishii; Kozo Hotta; Nobuya Higashitani; Yoshihiro Kato; Yasutaka Inuzuka; Chiyo Maeda; Toshikazu Jinnai; Yuko Morikami; Naritatsu Saito; Kenji Minatoya; Takeshi Aoyama; Takeshi Kimura
Journal:  Sci Rep       Date:  2018-07-04       Impact factor: 4.379

3.  Causes of Death in Patients with Severe Aortic Stenosis: An Observational study.

Authors:  Eri Minamino-Muta; Takao Kato; Takeshi Morimoto; Tomohiko Taniguchi; Hiroki Shiomi; Kenji Nakatsuma; Shinichi Shirai; Kenji Ando; Norio Kanamori; Koichiro Murata; Takeshi Kitai; Yuichi Kawase; Makoto Miyake; Chisato Izumi; Hirokazu Mitsuoka; Masashi Kato; Yutaka Hirano; Shintaro Matsuda; Kazuya Nagao; Tsukasa Inada; Tomoyuki Murakami; Yasuyo Takeuchi; Keiichiro Yamane; Mamoru Toyofuku; Mitsuru Ishii; Moriaki Inoko; Tomoyuki Ikeda; Akihiro Komasa; Eiji Tada; Katsuhisa Ishii; Kozo Hotta; Nobuya Higashitani; Toshikazu Jinnai; Yoshihiro Kato; Yasutaka Inuzuka; Chiyo Maeda; Yuko Morikami; Naritatsu Saito; Ryuzo Sakata; Kenji Minatoya; Takeshi Kimura
Journal:  Sci Rep       Date:  2017-11-07       Impact factor: 4.379

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.